Leo Lee Biography and Net Worth

Director of Insmed

Mr. Lee has been a member of our board since May 2018, bringing more than 20 years of experience in pharmaceutical innovation, commercialization, regulatory affairs, and policy, as well as extensive experience working in North America and Asia. Mr. Lee served as President, Japan of Novartis Pharma from 2020 to 2024, and became President, China of Novartis Pharma in 2024. Previously, Mr. Lee served as CEO of Regeneus Ltd, a global pharmaceutical company based in Australia, from 2019 to 2020, and as President, Japan, for Merck KGaA from 2015 to 2017. Prior to Merck KGaA, he served as President, Japan, for Allergan plc from 2011 to 2015, and as Vice President of Sales at Merck & Co. from 2008 to 2011. From 2003 to 2008, Mr. Lee held various commercial positions at IQVIA (Cegedim Dendrite), a life sciences services company. Mr. Lee also served in various roles at Accelrys, Inc., a software company serving pharmaceutical and biotech companies, from 1997 to 2003. Mr. Lee received a Bachelor of Science in Molecular Genetics and Microbiology from the University of California, Los Angeles. Mr. Lee is a member of the Compensation Committee and the Science & Technology Committee.

What is Leo Lee's net worth?: The estimated net worth of Leo Lee is at least $10.74 million as of November 17th, 2025. Mr. Lee owns 54,677 shares of Insmed stock worth more than $10,741,570 as of December 12th. This net worth evaluation does not reflect any other investments that Mr. Lee may own. Learn More about Leo Lee's net worth.
How do I contact Leo Lee?: The corporate mailing address for Mr. Lee and other Insmed executives is 700 US Highway 202/206, Bridgewater NJ, 08807. Insmed can also be reached via phone at 908-977-9900 and via email at [email protected]. Learn More on Leo Lee's contact information.
Has Leo Lee been buying or selling shares of Insmed?: Within the last three months, Leo Lee has sold $14,692,500.00 of Insmed stock. Most recently, Leo Lee sold 75,000 shares of the business's stock in a transaction on Monday, November 17th. The shares were sold at an average price of $195.90, for a transaction totalling $14,692,500.00. Following the completion of the sale, the director now directly owns 54,677 shares of the company's stock, valued at $10,711,224.30. Learn More on Leo Lee's trading history.
Who are Insmed's active insiders?: Insmed's insider roster includes Roger Adsett (COO), Elizabeth Anderson (Director), Sara Bonstein (CFO), David Brennan (Director), Clarissa Desjardins (Director), Clarissa Desjardins (Director), Martina Flammer (Insider), Leo Lee (Director), William Lewis (CEO), David McGirr (Director), Orlov Nicole Schaeffer (Insider), Melvin Sharoky (Director), Michael Smith (VP), and John Wise (Insider). Learn More on Insmed's active insiders.
Are insiders buying or selling shares of Insmed?: In the last year, Insmed insiders bought shares 2 times. They purchased a total of 3,025 shares worth more than $201,694.15. In the last year, insiders at the biopharmaceutical company sold shares 74 times. They sold a total of 1,482,921 shares worth more than $149,825,544.11. The most recent insider tranaction occured on November, 24th when Director Elizabeth M Anderson sold 5,000 shares worth more than $1,022,900.00. Insiders at Insmed own 3.0% of the company. Learn More about insider trades at Insmed.
Information on this page was last updated on 11/24/2025.

Leo Lee Insider Trading History at Insmed

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/17/2025	Sell	75,000	$195.90	$14,692,500.00	54,677

Leo Lee Buying and Selling Activity at Insmed

Insmed Company Overview

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Today's Range

Now: $197.01

$191.74

$198.13

50 Day Range

MA: $185.10

$158.28

$211.41

2 Week Range

Now: $197.01

$60.40

$212.75

Volume

1,781,017 shs

Average Volume

2,741,582 shs

Market Capitalization

$42.02 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01